Literature DB >> 15227729

Association of the gene polymorphisms of platelet glycoprotein Ia and IIb/IIIa with myocardial infarction and extent of coronary artery disease in the Korean population.

Sungha Park1, Hyun Young Park, Chanmi Park, Young Guk Ko, Eun Kyung Im, Inho Jo, Chol Shin, Jong Bok Lee, Won Heum Shim, Seung Yun Cho, Yangsoo Jang.   

Abstract

Platelet membrane receptor glycoproteins (GP) are essential for the platelet activation process, and the genetic polymorphisms in the genes that encode platelet glycoproteins have been proposed to influence the risk of acute coronary syndrome and atherosclerosis. In this study, we investigated the role of GPIa, HPA-1 and HPA-3 polymorphisms as putative risk factors for myocardial infarction (MI) and the extent of coronary artery disease. We selected 1,073 subjects who underwent coronary angiography; 242 had normal or minimal coronary atherosclerosis, and 831 patients had significant coronary artery disease (CAD). The genotype was determined by the methods of single base extension for C807T/G873A polymorphisms of GPIa, and restriction fragment length polymorphism for HPA-1 and HPA-3. The C807T and G873A polymorphisms of GPIa showed complete linkage in the Korean population. For HPA-1 gene polymorphism, only the HPA-1a/a (PlA1/A1) genotype was observed in 192 selected subjects from our study population. The distribution of GPIa (C807T/G873A) and HPA-3 genotypes did not differ significantly between normal subjects and CAD subjects. No significant association between MI and both gene polymorphisms was present. However, for the subgroup analysis of young male patients whose age was less than 56 years, the genotype frequency of HPA-3b/b was significantly lower in patients with MI compared to patients without a history of MI (7.5% vs. 20.0%, p=0.04). The odds ratio for HPA-3 b homozygosity versus the HPA-3a carrier was 0.32 (95% CI, 0.10- 0.99, p=0.04). Conclusively, HPA-3 polymorphism was associated with MI in Korean individuals younger than 56 years of age, but other polymorphisms of GP, which we studied, were not associated with both the extent of coronary atherosclerosis or MI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15227729     DOI: 10.3349/ymj.2004.45.3.428

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  6 in total

1.  Human platelet alloantigens HPA-1, HPA-2, and HPA-3 polymorphisms associated with extent of severe coronary artery disease.

Authors:  Nesrine Abboud; Lakdhar Ghazouani; Sonia Ben-Hadj-Khalifa; Fatma Anabi; Faouzi Added; Ali Khalfallah; Brahim Nsiri; Wassim Y Almawi; Touhami Mahjoub
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

2.  Allele frequencies of the human platelet antigen-1 in the Egyptian population.

Authors:  Abdel Halim Salem; Kyudong Han; Mark A Batzer
Journal:  BMC Res Notes       Date:  2009-05-20

3.  The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis.

Authors:  Christopher N Floyd; Agnesa Mustafa; Albert Ferro
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

4.  Association of human platelet alloantigens encoding gene polymorphisms with the risk of Coronary artery disease in Iranian patients.

Authors:  Farideh Malakootikhah; Hossein Naghavi; Negar Firouzabadi; Mohsen Maadani; Massoumeh Shafiei; Nader Tajik
Journal:  BMC Cardiovasc Disord       Date:  2021-02-02       Impact factor: 2.298

5.  Personalized medicine in coronary artery disease: insights from genomic research.

Authors:  Sang-Hak Lee; Dong-Jik Shin; Yangsoo Jang
Journal:  Korean Circ J       Date:  2009-04-28       Impact factor: 3.243

6.  Increased Prevalence of Glycoprotein IIb/IIIa Leu 33 Pro Polymorphism in End Stage Renal Disease Patients on Hemodialysis.

Authors:  Amein Al-Ali; Fahad Al-Muhanna; Samir Al-Mueilo; Emmanuel Larbi; Ali Al-Sultan; Abdullah Rubaish; Suad Al-Ateeq; Alhusain Al-Zaharani
Journal:  Int J Biomed Sci       Date:  2008-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.